Good response of membranous lupus nephritis to tacrolimus.

Published on Apr 1, 2006in Clinical Nephrology0.991
· DOI :10.5414/CNP65276
Mie Maruyama5
Estimated H-index: 5
(Okayama University),
Yasushi Yamasaki25
Estimated H-index: 25
(Okayama University)
+ 6 AuthorsHirofumi Makino98
Estimated H-index: 98
(Okayama University)
Sources
Abstract
A 22-year-old woman hospitalized for polyarthralgia was diagnosed with systemic lupus erythematosus (SLE). She was treated with prednisolone, and her clinical manifestations improved. However, she was re-admitted for renal biopsy because of persistent hypocomplementemia and development of proteinuria. The biopsy revealed segmental spike formation of basement membrane and subepithelial immune complex deposition, and membranous lupus nephritis (class V) was diagnosed. When tacrolimus was added to prednisolone, the serum complement titer quickly improved and proteinuria disappeared after about 11 months. Nevertheless, when tacrolimus was replaced examination showed cyclosporine due to gastrointestinal symptoms, she complained about arthralgia. Examination showed drop in the serum complement titer and recurrence of proteinuria. Renal biopsy at the time of recurrence showed increased subepithelial immune complex deposition in the capillary loops as compared to the first biopsy, a high degree of thickening of the basement membrane, and segmental circumferential interposition in some of the glomeruli. Membranous lupus nephritis (classes V + III) was diagnosed. By changing to tacrolimus and higher doses of steroids, the serum complement titer improved and proteinuria disappeared. This case indicates that tacrolimus can be an effective therapeutic agent for membranous lupus nephritis.
📖 Papers frequently viewed together
116 Citations
20072.25Lupus
5 Authors (KC Tse, ..., Tak Mao Chan)
60 Citations
20085.61Rheumatology
8 Authors (Cheuk-Chun Szeto, ..., P. K.-T. Li)
100 Citations
References0
Newest
Cited By16
Newest
#1Hiroshi TanakaH-Index: 28
#2Kazushi TsurugaH-Index: 17
Last. Tadaatsu ImaizumiH-Index: 46
view all 5 authors...
Recent advances in the management of lupus nephritis, together with earlier renal biopsy and selective use of aggressive immunosuppressive therapy, have contributed to a favorable outcome in children and adolescents with systemic lupus erythematosus (SLE). Nevertheless, we believe that a more effective and less toxic treatment is needed to attain an optimal control of the activity of lupus nephritis. Recent published papers and our experiences regarding treatment of young patients with lupus nep...
9 CitationsSource
#1Hidetoshi KagawaH-Index: 4
#2Tsutomu HiromasaH-Index: 1
Last. Hirofumi Makino (Okayama University)H-Index: 98
view all 7 authors...
Background Conventional cyclophosphamide-based treatment regimens for lupus nephritis (LN) are still not considered to be optimal. The aim of this study was to evaluate the efficacy and safety of mizoribine, tacrolimus, and corticosteroid combination therapy for LN.
12 CitationsSource
#1Hiroshi TanakaH-Index: 28
#2Tadaatsu ImaizumiH-Index: 46
Optimal treatment for lupus nephritis in adolescents is still a great challenge. Systemic lupus erythematosus (SLE) is a chronic disease characterized by frequent disease flares for which effective and safe maintenance therapy is required (Chan et al., 2005; Lai et al., 2005). Since diffuse proliferative lupus nephritis (DPLN) is a major concern regarding treatment of young patients with SLE, the optimal immunosuppressive therapy for controlling the activity of DPLN in this population remains co...
Source
Source
#1Earl D. SilvermanH-Index: 89
#2Allison A. EddyH-Index: 53
16 CitationsSource
#1Lee T (Seoul National University Hospital)H-Index: 1
#1Tae-Woo Lee (Seoul National University Hospital)H-Index: 5
Last. Ho Jun Chin (Seoul National University Bundang Hospital)H-Index: 30
view all 8 authors...
We conducted an open-labeled, prospective study to determine the efficacy and safety of tacrolimus as an alternative therapeutic option for those patients with refractory lupus nephritis. The study population comprised one male and eight female patients with diffuse proliferative lupus nephritis. All patients had failed to respond to sufficient intravenous cyclophosphamide therapy with proteinuria of ≥1 g/day and active urinary sediments. Tacrolimus (0.1 mg/kg/day) was administered for 1 year wi...
33 CitationsSource
Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disease with involvement of both B cells and cytotoxic T lymphocytes and several cytokines aberrations. Standard therapy for SLE has its limitations. Tacrolimus, a novel calcineurin inhibitor with potent immunosuppressive effects, has been shown in the recent years to be effective in SLE therapy. This paper serves to collate the experimental and clinical data on the efficacy of tacrolimus in the treatment of SLE and lupus nephri...
31 CitationsSource
#1Cristina Lanata (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 8
#2T. Mahmood (St. Agnes Hospital)H-Index: 1
Last. Michelle Petri (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 133
view all 4 authors...
Since most lupus nephritis patients have an incomplete response to mycophenolate mofetil, combination regimens may improve outcomes. Tacrolimus (FK506) has shown some benefit in lupus nephritis in small trials, and combined with mycophenolate mofetil is standard immunosuppression in transplant patients. We investigate the addition of FK506 to mycophenolate mofetil, in patients who were mycophenolate mofetil failures. All patients were part of a prospective cohort, but evaluated retrospectively. ...
47 CitationsSource
#1Hiroshi Tanaka (Hirosaki University)H-Index: 28
#2Eishin OkiH-Index: 14
Last. Etsuro ItoH-Index: 50
view all 6 authors...
Aims: Studies on immunosup- pressive treatment with tacrolimus (Tac) in subjects with lupus nephritis (LN) are lim- ited. Here, we report our experience with Tac administered daily as a single-dose for main- tenance therapy in young patients with pediatric-onset, long-standing LN. Methods: Eleven consecutive patients with long-stand- ing biopsy-proven LN were recruited for at least 6 months or longer (6 - 24 months) as part of an open-label trial for the single- daily-dose administration of Tac ...
29 Citations
Membranous nephropathy is an uncommon form of lupus nephritis, accounting for only one-fifth of all cases. As a result, few reviews have focused on this condition. Here, Chi Chiu Mok summarizes the histological classification, clinical presentation, outcomes and therapy of membranous lupus nephropathy. As the optimal therapy for this form of lupus nephritis remains unclear, the author provides an algorithm to help guide treatment.
52 CitationsSource